目的：观察自拟参附贞芪汤联合利伐沙班治疗慢性心衰的临床效果。方法：选取80例慢性心衰患者随机分为对照组与观察组,对照组患者接受常规治疗+利伐沙班治疗,观察组患者在对照组基础上加用自拟参附贞芪汤治疗。比较两组患者主要临床症状改善情况、血清氨基末端脑利钠肽前体（NT-pro BNP）水平、6 min步行距离、心功能改善情况及治疗效果。结果：观察组患者心悸、气短等临床症状消失时间短于对照组。两组患者面肢浮肿、口干以及气喘等临床症状消失时间差异无统计学意义。观察组患者治疗后血清NT-pro BNP水平低于对照组;观察组患者治疗后6 min步行距离远于对照组。治疗后,观察组患者左室收缩末期内径（LVESD）、左室舒张末期内径（LVEDD）、左室舒张时间（LVRT）均显著低于对照组,射血分数（EF）显著高于对照组。观察组患者治疗后总有效率高于对照组。结论：自拟参附贞芪汤联合利伐沙班治疗慢性心衰,可减轻患者临床症状,降低血浆NT-pro BNP水平,增加6 min步行距离,改善心肌功能,适于在临床推广应用。

Objective To observed the clinical effect of self-proposed Shenfu Zhenqi Tang combined with rivaroxaban in treating chronic heart failure. Methods 80 patients with chronic heart failure were randomly divided into the control group and the observation group, and the control group received conventional treatment + rivaroxaban treatment. The observation group received conventional treatment + rivaroxaban. The observation group was treated with self-proposed Shenfu Zhenqi Tang based on the control group. The two groups were compared regarding improvement of major clinical symptoms, serum NT-pro BNP level, 6-min walking distance, improvement of cardiac function, and therapeutic effect. Results The disappearance time of clinical symptoms such as palpitation and shortness of breath in the observation group was shorter than in the control group. There was no statistically significant difference between the two groups in the disappearance time of clinical symptoms such as facial limb swelling, dry mouth, shortness of breath, chest tightness, and cough. The serum NT-pro BNP level after treatment in the observation group was lower than that in the control group. The 6-minute walking distance after treatment in the observation group was much longer than that in the control group. After treatment, LVESD, LVEDD, and LVRT of the observation group were significantly lower than those of the control group, and EF was significantly higher than that of the control group. The total effective rate after treatment in the observation group was higher than in the control group. Conclusion Self-designed Shenfu Zhenqi Tang combined with rivaroxaban in treating of chronic heart failure can reduce clinical symptoms, lower plasma NT-pro BNP level, increase 6-minute walking distance, improve myocardial function, and be suitable for clinical application.